AMENDMENTS TO THE CLAIMS

- 1. (Previously presented) A method of alleviating symptoms of a psychological condition selected from the group consisting of depression, anxiety disorders, panic attacks, premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS) comprising administering to a subject in need thereof nerve growth factor in an amount effective to treat one or more symptoms of said psychological condition.
- 2. (Original) The method of claim 1, wherein said psychological condition is depression.
 - 3. (Canceled)
- 4. (Original) The method of claim 1, wherein said psychological condition is an anxiety disorder.
- 5. (Original) The method of claim 1, wherein said psychological condition is panic attacks.
 - 6.-7. (Cancelled)
- 8. (Original) The method of claim 1, wherein said psychological condition is premenstrual dysphoric disorder (PMDD).
- 9. (Original) The method of claim 1, wherein said psychological condition is premenstrual syndrome (PMS).

10. (Original) The method of claim 1, wherein said nerve growth factor is administered by a mode selected from the group consisting of sublingual, bucal, oral drench, subcutaneous, intradermal, or intravenous.

Docket No.: 13024/38627A

- 11. (Original) The method of claim 10, wherein said nerve growth factor is administered sublingually.
- 12. (Original) The method of claim 1, wherein said nerve growth factor is administered at a daily dosage of/from 0.001 to 1 microgram per day.
- 13 (Original) The method of claim 1, wherein said nerve growth factor is administered at a daily dosage of from 0.01 to 0.1 microgram per day.
- 14. (Previously presented) The method of claim 1, wherein the symptoms are selected from a group consisting of sleep disorders, tension headaches, cold sweats, and constipation.
- 15. (Previously presented) A method of alleviating symptoms of a psychological condition selected from the group consisting of sleep disorders, tension headaches, and constipation comprising administering to a patient in need thereof nerve growth factor in an amount effective to treat one or more said symptoms.
 - 16. (Original) The method of claim 15, wherein said symptom is a sleep disorder.
- 17. (Original) The method of claim 15, wherein said symptom is a tension headache.
 - 18. (Original) The method of claim 15, wherein said symptom is constipation.

Docket No.: 13024/38627A

19. (Cancelled)

- 20. (Original) The method of claim 15, wherein said nerve growth factor is administered by a mode selected from the group consisting of sublingual, bucal, oral drench, subcutaneous, intradermal, or intravenous.
- 21. (Original) The method of claim 20, wherein said nerve growth factor is administered sublingually.
- 22. (Original) The method of claim 15, wherein said nerve growth factor is administered at a daily dosage of/from 0.001 to 10 micrograms per day.
- 23. (Original) The method of claim 15, wherein said nerve growth factor is administered at a daily dosage of/from 0.05 to 1 micrograms per day.
- 24. (Original) The method of claim 15, wherein said nerve growth factor is administered at a daily dosage of/from 0.01 to 0.1 micrograms per day.

25-28. (Canceled)

4